MALARI A drug made in yeast causes market ferment

Synthetic biology delivers combination therapies into an uncertain market.

BY MARK PEPLOW

“...it’s been a dream project — but it’s been a long dream,” says Jay Keasling, a biochemical engineer at the University of California, Berkeley. Seven years ago, he and his team genetically engineered yeast to produce artemisinic acid (D.-K. Ro et al. Nature 440, 940–943; 2006), a precursor to the best malaria treatments available: artemisinin-based combination therapies (ACTs). Synthetic biology, Keasling hoped, could produce the drug more cheaply and reliably than natural sources, benefiting the roughly 200 million people infected with malaria each year.

Keasling’s pipe dream has turned into a drug pipeline. In 2008, Paris-based pharmaceutical company Sanofi licensed the yeast that he helped to develop, and at an artemisinin conference in Nairobi last month, Keasling learned that the company had produced almost 39 tonnes of artemisinic acid — the first industrial-scale deployment of synthetic biology for drug production. The stock could be converted to at least 40 million treatments, says Keasling.

But the elegant science faces some messy realities. This year will see the end of one of the main funding routes for ACTs — the Affordable Medicines Facility — Malaria (AMFm) programme, run by the Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva, Switzerland. Its demise may not leave enough alternative funding to pay for the extra treatments made possible by the semi-synthetic process. Furthermore, if Sanofi’s product is rushed into pharmacies at similar prices to existing products, it could disrupt an already volatile market (see Nature 466, 672–673; 2010). “If it’s brought in too fast it could create huge shortages, because people will stop producing the natural stuff,” says Malcolm Cutler, technical adviser to the Assured Artemisinin Supply System initiative, which organized the Nairobi conference.

The sweet wormwood plant, Artemisia annua, has until now been the only source of artemisinin. Drug-makers convert the natural product into derivatives that are more easily taken up by the body, and then combine them with other drugs to prevent the malaria parasite from developing resistance. Since 2005, when ACTs became the preferred treatment of the World Health Organization (WHO), governments and health policy-makers have encouraged farmers in China, Vietnam and elsewhere to grow A. annua to meet rising demand. But the dependence on erratic donor funding, along with a production cycle that can take a year and a half from planting to drug production, has made it difficult to manage that supply. Last year, a bumper crop of A. annua and fears of declining funding sent artemisinin prices plummeting (see “The cost of progress”).

Yeast make ACT production faster and more manageable. The microbes are not affected by weather, and they churn out artemisinic acid that is readily turned into semi-synthetic artemisinin, which Sanofi or other makers can convert into ACT ingredients such as artesunate. The whole process takes less than three months. “You get an order, you fire up the bioreactors, and you ship it out,” says Keasling. Sanofi hopes to get WHO approval for semi-synthetic artemisinin in the coming months, says Ponni Subbiah, a drug-development programme leader at PATH, a global health organization based in Seattle, Washington, which has funded and coordinated the development of semi-synthetic artemisinin.
PUBLISHING

Company offers portable peer review

Author-pays service cuts down on redundant reviews.

BY RICHARD VAN NOORDEN

Researchers waiting for their manuscript to emerge from multiple rounds of peer review as it bounces from journal to journal can easily get frustrated at the inefficiencies of the system. Soon they may have another option: paying for a fast, independent peer review that could travel with the paper from one journal to another.

The concept comes from a company called Rubriq. Charging authors an estimated US$500–700 for its service, the firm plans to offer a standard-format anonymized review, and is currently testing its concept with publishers including Public Library of Science (PLoS), Karger, F1000Research and Wiley, as well as more than 500 reviewers. The company — owned by research software and services firm Research Square in Durham, North Carolina — is one of a number of firms hoping to capture some of that demand that there is a gap in the market. “Millions of hours of work are spent every year on redundant reviews,” he says. Collier has experience: he was previously general manager of ScholarOne, a widely used peer-review service based in Charlottesville, Virginia, and owned by Thomson Reuters. He estimates that around 50% of articles are initially rejected. Every resubmission can lead to another round of peer review, delaying publication and costing time and money.

Recognizing the problem, journals are increasingly passing on their rejected papers with peer reviews attached; but such transfers tend to take place only within a publisher. Matthew Cockerill, managing director of BioMed Central (BMC) in London, says that BMC’s Genome Biology accepts around 10% of submitted papers, but passes on 40% of those it rejects to other BMC journals together with the peer reviews; of those, around 50% are published somewhere within the BMC group.

Publishers are trying to share reviews more broadly: both BMC and PLoS are now working with the open-access journal eLife to explore passing on peer reviews with rejected papers, Cockerill says. But an early effort to do so — an alliance of neuroscience journals that in 2008 agreed to accept manuscript reviews from one another — has met with limited success. Before the scheme, journal editors who were wedded to their own peer-review standards “seemed more likely to use one another’s toothbrushes than their review formats,” says Clifford Saper, a former co-chair of the consortium. Even today, only 1–2% of rejected papers within the group are shared with other journals, says John Maunsell, a current co-chair.

Collier is betting that journals will accept the standardized peer-review form it has created, which follows the example of a similar organization called Peerage of Science, based in Jyväskylä, Finland. That service has signed up a community of more than 1,100 scientists and has processed 67 manuscripts. Authors pay nothing. Instead, journals subscribe to the service and are charged up to €400 (US$540) for each manuscript they accept (three have been published in this way so far). Scientists can also point other prospective publishers to the reviews of their papers.

Rubriq’s emphasis is on speed. By paying peer reviewers $100 each, it hopes to get reviews back within a week. That payment will not compensate a reviewer for his or her time (which economic analyses have estimated as worth on the order of $400 per review) but it could start to professionalize what has historically been a voluntary role, Collier says. The payments are covered by Rubriq’s fee to authors, which also covers the administrative burden of recruiting reviewers and assigning papers — an estimated $200. (In addition, if the journal and the funding body agree, the payments may be covered by the institutional support that the institution provides to its author.)

Rubriq also hopes that its service will help to create a market for journals’ rejected papers. “We are talking to a number of journals,” says Collier. “Many are very interested,” he adds. It has already announced a number of arrangements with journals, including those of the open-access PLoS, Karger, F1000Research and Wiley.